GLPwatch
Wegovy for Depression
semaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCWegovy (semaglutide) is not FDA-approved for depression, and any use for this condition is off-label or investigational. The listed research includes studies examining psychiatric adverse events, suicidal ideation, and potential mood-related effects, but does not establish efficacy for treating depression.
AI summary of the sources below.
| Drug | Wegovy (semaglutide) |
|---|---|
| Condition | Depression |
| Approval status | Investigational / off-label |
| Research papers | 22 |
Wegovy is not FDA-approved for depression; the research below reflects investigational or off-label study only.
Research on semaglutide for depression (22)
- Association of semaglutide with risk of suicidal ideation in a real-world cohort.
- Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality.
- Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials.
- Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.
- Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis.
- Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline: A post hoc subgroup analysis.
- Semaglutide in Psychiatry-Opportunities and Challenges.
- Semaglutide, suicidal ideation and behaviour: A resting state functional magnetic resonance imaging perspective.
- Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A vigibase study.
- Semaglutide as a possible therapy for healthy aging: Targeting the hallmarks of aging.
- Depression and suicide/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database.
- Beyond Diabetes: Semaglutide's Role in Modulating Mood Disorders through Neuroinflammation Pathways.
- Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population-based cohort study.
- Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial.
- Semaglutide and risk of suicidal ideations.
- Association of semaglutide use with depressive symptoms and suicidal behavior in a patient with type 2 diabetes: A case report.
- Semaglutide: A New Medical Swiss Army Knife?
- Great Expectations: Semaglutide as Antidiabetic Weight Management in a Psychiatric Hospital.
- Clustering of intuitive eating and psychological health identifies subgroups associated with weight loss following semaglutide.
- [Effects of semaglutide on mental health].
- Semaglutide Linked With Lower Risk of Suicidal Thoughts.
- The Effect of Semaglutide With Lifestyle Intervention on the Physical Health of Patients Treated With Antipsychotic Drugs in a Secure Mental Health Setting: Protocol for an Uncontrolled Pretest-Posttest Pilot Mixed Methods Study.